Rocket Lab Corporation is trading at $80.25 — flat on the week, still below the ceiling its own CEO set, and with short sellers now holding a slightly rebuilt position after covering into earnings.
The most important update since the prior note is a small but real reversal in short positioning. SI had pulled back to 8.7% of the free float after shorts covered into the August 10 earnings print. It has now ticked back up fractionally — rising 0.08% on the day and 13% over the past month in aggregate. That month-long build is the context that matters: despite the post-earnings dip, shorts have added roughly 5.4 million shares since early July. The borrow market remains relaxed about all of this. Availability is at 274%, meaning nearly three shares are loanable for every one already shorted. Cost to borrow has fallen 19% on the week to just 0.42% — the lowest in the 30-day window. The lending market is not registering stress, and at a short score of 53.5 — broadly mid-range — there is no ORTEX-level signal of a squeeze setup forming.
Options reinforce the neutral-to-slightly-bullish lean. The put/call ratio is 0.70, barely above its 20-day average of 0.69 and less than one standard deviation from the mean. The 52-week range runs from 0.36 to 0.85, putting the current reading squarely in the middle of recent history. There is no meaningful defensive rotation visible in the options market right now.
The insider overhang is the one signal that hasn't changed — and at this price, that matters. Peter Beck sold more than 1.6 million shares across July 7–8 at prices ranging from $81 to $89. At $80.25, RKLB has nearly recovered to the bottom of that range but hasn't cleared it. Net insider activity over the trailing 90 days totals approximately $302 million in sales with zero offsetting purchases. Every prior note in this series has flagged that range as the ceiling until proved otherwise. Nothing in this week's data contradicts that read. The stock is now within striking distance — but striking distance is not a breakout.
Institutional flows show broad-based accumulation. BlackRock added 2.6 million shares in its most recent filing, JP Morgan Asset Management added another 2.6 million, and Vanguard's two vehicles collectively added roughly 2.7 million shares. That is a meaningful passive and active bid supporting the stock. Peer LUNR had a sharply different week — up nearly 16% — while RDW was essentially flat and FLY edged lower. RKLB's 3% weekly decline puts it in the softer half of the peer group, though its year-to-date momentum trajectory remains structurally stronger than most of the cohort.
The valuation picture is extreme by conventional measures — a PE ratio above 5,000 and an EV/EBITDA near 1,024 — but this is a growth story priced on forward revenue multiples and Neutron development optionality, not on current earnings. The EPS surprise factor score ranks in the 90th percentile, which is the one fundamental that keeps bulls anchored. EPS momentum over 30 days, however, sits at the first percentile — a sharp divergence that points to near-term estimate pressure even as the long-run growth case stays intact.
The key watch for the coming sessions is whether $80–81 holds as resistance or becomes support. Beck's lowest July sale was at $81.49. A clean close above that level on volume would represent the first time the market has absorbed the full range of insider supply — and the first real test of whether institutional accumulation can overpower the ceiling the CEO himself set.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
